tiprankstipranks

BofA moves to No Rating on Enfusion after Clearwater Analytics deal

BofA analyst Koji Ikeda is moving to No Rating on Enfusion (ENFN) after it was announced that the investment management vertical software vendor is being acquired by Clearwater Analytics (CWAN) for $1.5B in a mix of cash and stock. Given Enfusion’s current growth and profitability profile, the firm believes the acquisition price is “reasonable,” adding that it believes shares are no longer trading on fundamentals due to the proposed acquisition.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue